Talphera Inc. (TLPH)
Talphera Inc. (TLPH) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 1K |
| Net Income (ttm) | -15.08M |
| Beta | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.02 |
| P/B (ttm) | 3.33 |
| P/S (ttm) | 63836.57 |
| Earnings Date | Nov 11, 2026 |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | n/a |
| Price Target | 3 (NaN%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coa...
Financial Performance
In 2025, Talphera's revenue was 28K, an increase of undefined% compared to the previous year's 0. Earnings were -14.29M, an increase of 9.89%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for TLPH stock is "null". The 12-month stock price forecast is 3, which is downside of NaN% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
